MedTrace Logo

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

NCT02509481 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 2712

Last updated 2019-01-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in treated village children.

Conditions

Interventions

DRUG

Ivermectin

DRUG

Albendazole

Sponsors & Collaborators

  • Institut de Recherche en Sciences de la Sante, Burkina Faso

    collaborator OTHER_GOV

  • Centre Muraz

    collaborator OTHER

  • Ministère de la Santé du Burkina Faso

    collaborator UNKNOWN

  • Colorado State University

    lead OTHER

Principal Investigators

  • Brian D. Foy, PhD · Colorado State University

  • Roch K Dabire, PhD · Institute de Recherche en Sciences de la Santé

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • United States
  • Burkina Faso

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02509481 on ClinicalTrials.gov